The White House is defending the Federal Drug Administration's decision to stop the use of antibody drugs that don't work against omicron. This comes after the Food and Drug Administration said it was revoking emergency authorization for Regeneron and Eli Lilly, which were purchased by the federal government and have been administered to millions of Americans with COVID-19. If the drugs prove effective against future variants, the FDA said it could reauthorize their use. The regulatory move was expected because both drugmakers had said the infusion drugs are less able to target omicron due to its mutations. Still, the federal action could trigger pushback from some Republican governors who have continued promoting the drugs against the advice of health experts.